Detalhe da pesquisa
1.
Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic modelling study.
Lancet Reg Health Am
; 24: 100543, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37366432